# Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

> **NCT01868568** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 55 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin degludec/insulin aspart 30
- **DRUG:** insulin degludec/insulin aspart 40
- **DRUG:** insulin degludec/insulin aspart 45
- **DRUG:** insulin degludec/insulin aspart 55
- **DRUG:** insulin aspart
- **DRUG:** biphasic insulin aspart 30
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01868568
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2015-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01868568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01868568, "Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01868568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*